A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 353 participants.

Also called NCT04998981

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 353 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04998981
Other papers using this trial's data
  • Efficacy and Safety of Pemafibrate, a Novel Selective PPARα Modulator in Chinese Patients with Dyslipidemia: A Double-Masked, Randomized, Placebo- and Active-Controlled Comparison Trial Journal of atherosclerosis and thrombosis, 2025-02-01 DOI, PubMed 39098034, PMC11802246 In the PMC Open Access subset under CC BY-NC-SA.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04998981. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-17 (actual); primary completion 2023-02-02 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C
Condition
Hyperlipidemia
Intervention (Drug)
K-877 0.1 mg tablet
Intervention (Drug)
Fenofibrate 200 mg capsule
Intervention (Drug)
Placebo tablet
Intervention (Drug)
Placebo capsule
Intervention (Drug)
K-877 0.1 mg tablet
Intervention (Drug)
Placebo tablet
Lead sponsor
Kowa Company, Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04998981
Content hash
977c9a5b6de6a485a94d4a9213f9d2572a2f9eac55873b9472ebb11c63dfb6f9